Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Aug 8, 2024
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q’25
Strong financial position with cash and cash equivalents totaling $255.3 million as of June 30, 2024
Read more at globenewswire.com
